Long-Term Cardiac Safety of Dose-Dense Anthracycline Therapy Cannot Be Predicted From Early Ejection Fraction Data
Authors:
- 20 December 2009
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (36) , 6073-6075
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Dose-Dense Adjuvant Doxorubicin and Cyclophosphamide Is Not Associated With Frequent Short-Term Changes in Left Ventricular Ejection FractionJournal of Clinical Oncology, 2009
- Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31Journal of Clinical Oncology, 2005
- Formulae for Predicting the Likelihood of Developing Congestive Heart Failure Following Anthracycline Chemotherapy: Added Evidence for Early CardiotoxicityJournal of Cardiac Failure, 2005
- Congestive heart failure in patients treated with doxorubicinCancer, 2003
- Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapyAnnals of Oncology, 2002
- A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin.Journal of Clinical Oncology, 1984
- Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous InfusionAnnals of Internal Medicine, 1982
- Late, Late Doxorubicin CardiotoxicityChest, 1980